In the old days, back in April, the big news everyone was waiting for from Pfizer was whether it would go ahead and file for FDA approval of its star pipeline drug palbociclib on Phase II data alone. The answer, signaled by the rolling of the drums Friday as trading in Pfizer's shares was momentarily suspended, was yes. But as Pfizer had recently shifted the primary focus to its wholly unexpected...
Why did Pfizer's big fiesta for palbociclib fizzle?
The craft of opposition research—finding information that might put an opponent in a negative light—has long been a staple of political campaigns. This year, independent groups are taking a leading role....
Cynthia Quarterman, a top U.S. safety regulator tasked with handling the U.S. government's response to a string of oil-train crashes in recent years, is stepping down....
The Los Angeles City Council has approved one of the nation's highest minimum wages for workers at the city's large hotels....
The U.S. government will pay the Navajo Nation $554 million to settle long-standing claims that it mismanaged funds and natural resources on the tribe's reservation for years....
Connecticut gubernatorial candidate Joe Visconti opposes the state's new gun restrictions, and he has an online commercial that shows him riding in a 1974 Pontiac convertible with rifles fixed to the rear fenders. ...
The U.S. and Arab allies launched a second major wave of airstrikes in Syria targeting mobile oil refineries controlled by Islamic State, the Pentagon said....